CAJ | 학술논문

目的：探讨别嘌醇与苯溴马隆在治疗高尿酸血症小鼠时对小鼠糖代谢水平的影响。方法腹腔注射尿酸造成小鼠高尿酸血症模型,动物分为正常对照组、高尿酸组、别嘌醇组和苯溴马隆组,给予相应药物14 d与28 d后,取静脉血检测各组小鼠血尿酸值、空腹血糖值、20 d糖耐量、24 d胰岛素耐量等因素的变化水平。结果高尿酸模型小鼠血尿酸水平显著上升(P<0.01),空腹血糖值显著增加(P<0.01),糖耐量与胰岛素耐量的实验中,高尿酸小鼠在各时间点的血糖值与正常对照组比较差异均有统计学意义(P<0.05或P<0.01)。给予苯溴马隆与别嘌醇干预后,苯溴马隆组在14 d与28 d将血尿酸值分别降至(35.58±6.31)mg/L和(67.37±7.15)mg/L(P<0.01),空腹血糖值为(8.13±0.51)mmol/L和(8.18±0.82)mmol/L；别嘌醇组血尿酸值更低,分别为(25.37±9.08)mg/L和(22.97±4.26)mg/L(P<0.01),空腹血糖为(9.62±0.48)mmol/L和(9.82±0.53)mmol/L。对于糖耐量和胰岛素耐量的考察发现,口服葡萄糖后,苯溴马隆组小鼠在30、60、120 min时血糖水平分别为(20.14±2.01)、(13.14±1.32)、(9.74±1.32)mmol/L,与高尿酸组比较,呈现显著下降趋势(P<0.05或P<0.01),而别嘌呤组未见明显差异。注射胰岛素后,苯溴马隆组在30、60、90、120 min时血糖值分别为(4.97±0.25)、(4.15±0.25)、(4.13±0.78)、(4.77±0.66)mmol/L,与高尿酸组比较,差异有统计学意义(P<0.05或P<0.01),而别嘌醇组则未见这样的作用。结论别嘌醇与苯溴马隆在治疗高尿酸血症时均有很好的作用,而苯溴马隆具有纠正糖负荷或胰岛素负荷下血糖异常的作用,所以对于合并血糖升高时,苯溴马隆对高尿酸引起的异常的空腹血糖值、胰岛素耐量与糖耐量的调控更有优势。
목적：탐토별표순여분추마륭재치료고뇨산혈증소서시대소서당대사수평적영향。방법복강주사뇨산조성소서고뇨산혈증모형,동물분위정상대조조、고뇨산조、별표순조화분추마륭조,급여상응약물14 d여28 d후,취정맥혈검측각조소서혈뇨산치、공복혈당치、20 d당내량、24 d이도소내량등인소적변화수평。결과고뇨산모형소서혈뇨산수평현저상승(P<0.01),공복혈당치현저증가(P<0.01),당내량여이도소내량적실험중,고뇨산소서재각시간점적혈당치여정상대조조비교차이균유통계학의의(P<0.05혹P<0.01)。급여분추마륭여별표순간예후,분추마륭조재14 d여28 d장혈뇨산치분별강지(35.58±6.31)mg/L화(67.37±7.15)mg/L(P<0.01),공복혈당치위(8.13±0.51)mmol/L화(8.18±0.82)mmol/L；별표순조혈뇨산치경저,분별위(25.37±9.08)mg/L화(22.97±4.26)mg/L(P<0.01),공복혈당위(9.62±0.48)mmol/L화(9.82±0.53)mmol/L。대우당내량화이도소내량적고찰발현,구복포도당후,분추마륭조소서재30、60、120 min시혈당수평분별위(20.14±2.01)、(13.14±1.32)、(9.74±1.32)mmol/L,여고뇨산조비교,정현현저하강추세(P<0.05혹P<0.01),이별표령조미견명현차이。주사이도소후,분추마륭조재30、60、90、120 min시혈당치분별위(4.97±0.25)、(4.15±0.25)、(4.13±0.78)、(4.77±0.66)mmol/L,여고뇨산조비교,차이유통계학의의(P<0.05혹P<0.01),이별표순조칙미견저양적작용。결론별표순여분추마륭재치료고뇨산혈증시균유흔호적작용,이분추마륭구유규정당부하혹이도소부하하혈당이상적작용,소이대우합병혈당승고시,분추마륭대고뇨산인기적이상적공복혈당치、이도소내량여당내량적조공경유우세。
Objective To explore the effects on glucose metabolism when Allopurinol and Benzbromarone in the treat-ment of hyperuricemia. Methods Hyperuricemia model mice caused by intraperitoneal injection of uric acid. Animals were divided into normal control group, high uric acid group, Allopurinol group and Benzbromarone group. After 14 d and 28 d administration, the levels of uric acid, fasting glucose, 24 d insulin tolerance and 20 d glucose tolerance in blood of mice in each group were tested. Results Significant differences in uric acid levels and blood sugar levels in blood were found, after comparing between the model group and the control group (P< 0.01). Model group had signifi-cant differences compared with the control group for blood glucose at the time point, in experiments of glucose toler-ance and insulin resistance (P< 0.05 or P< 0.01). The uric acid levels of Benzbromarone group decreased to (35.58±6.31) mg/L and (67.37±7.15) mg/L after 14 d and 28 d of administration (P<0.01), while fasting glucose values were (8.13±0.51) mmol/L and (8.18±0.82) mmol/L. In the Allopurinol group after 14 d and 28 d of administration, the uric acid levels were (25.37±9.08) mg/L and (22.97±4.26) mg/L (P< 0.01), fasting glucose values were (9.62±0.48) mmol/L and (9.82±0.53) mmol/L. Blood glucose values were (20.14±2.01), (13.14±1.32), (9.74±1.32) mmol/L at 30, 60, 120 min after oral glucose in Benzbromarone group. Compared with the model group, showed a downtrend (P < 0.05 or P <0.01). However, there was no significant difference between Allopurinol group and model group. Blood glucose values were (4.97±0.25), (4.15±0.25), (4.13±0.78), (4.77±0.66) mmol/L at 30, 60, 90, 120 min after the injection of insulin in the Benzbromarone group. The values showed a significant difference compared with the model group (P< 0.05 or P<0.01). However, there was also no significant difference between Allopurinol group and model group. Conclusion Al-lopurinol and Benzbromarone play good role in the treatment of hyperuricemia. However, in the treatment of diabetic patients with hyperuricemia, Benzbromarone has more advantages than Allopurinol.